Women are facing an alarming surge in lung cancer, a shift that many experts say was years in the making. While breast cancer remains the most common, lung cancer is now the deadliest for women, overtaking breast cancer in mortality. The trend is accelerating, with thousands of new cases each year, and the burden falling disproportionately on female patients.
What’s driving the surge?
The primary driver is the historic rise in smoking among women during the late 20th century. Lung cancer risk follows a long lag, and today’s diagnoses reflect smoking patterns from 20 to 40 years ago. As one French physician warned, “We are seeing the explosion of cancers decades after the boom in female smoking.”
But tobacco is no longer the sole explanation, and that is deeply concerning. Clinicians report more lung cancers in people who have never smoked, and a growing share are women. One surgeon noted that nearly one in five lung cancer patients today never smoked, prompting scrutiny of air pollution and possible hormonal influences.
Why women may face higher risk
Evidence suggests women may be more susceptible to tobacco’s carcinogens at comparable exposure levels. Some specialists report that women develop lung cancer at the same age as men despite lower cumulative smoking, or earlier at the same dose. This could reflect biological differences, interactions with hormones, or variations in how carcinogens are processed.
Environmental factors compound the risk, especially long-term exposure to fine particulates and nitrogen oxides in urban air. Secondhand smoke, certain workplace exposures, and indoor pollutants like radon also pose hazards. These risks help explain why lung cancer is not exclusively a smoker’s disease, and why vigilance must extend beyond tobacco.
The French picture in numbers
In France, tobacco still causes about 75,000 deaths a year, roughly 200 each day. Among women, new lung cancer diagnoses climbed to around 20,000 in recent years, with an annual rise of about 4.3%. While male incidence has stabilized in some regions, the burden among women continues to grow.
“Lung cancer has become the most lethal cancer in women, ahead of breast cancer,” noted one physician during a televised segment. The statement underscores a sobering reality: mortality reflects both late diagnosis and the aggressive nature of certain tumors.
The case for earlier detection
Unlike breast or colorectal cancer, there is no nationwide, organized lung cancer screening program in many countries. France has launched a pilot called IMPULSION, targeting 50–74 year-old current and recent ex-smokers. Participants undergo low-dose chest CT scans at defined intervals, coupled with structured cessation support.
Low-dose CT has been shown to detect tumors earlier, when surgery or targeted therapy can be more effective. Modeling suggests that combining screening with cessation could reduce mortality significantly—by as much as 38% in certain scenarios. The hope is to scale evidence-based screening while minimizing harms like false positives and overdiagnosis.
Prevention you can act on
Prevention remains the most powerful tool against lung cancer. Quitting smoking delivers rapid and long-term benefits, reducing risk year after year. One clinician urged, “Talk to your doctor, a tobacco specialist, or a trained counselor—quitting works best with a real team behind you.”
Practical steps include:
- Setting a firm quit date and arranging behavioral support
- Using nicotine replacement or prescribed cessation medications
- Testing your home for radon and improving indoor ventilation
- Reducing exposure to secondhand smoke and urban pollution
- Staying alert to persistent cough, chest pain, or unexplained weight loss
Treatment is improving—but timing matters
On the treatment front, advances in targeted therapies, immunotherapies, and minimally invasive surgery are extending survival. Molecular testing can match tumors to precise drugs, especially in non-smokers who more often carry actionable mutations. Yet these breakthroughs work best when cancers are found early, before widespread spread.
That is why awareness and equitable access are crucial for women, who too often face delayed diagnoses. Primary care clinicians, gynecologists, and pulmonologists can all play a role by assessing risk, discussing symptoms, and guiding timely imaging.
A public health priority
The rising toll among women should galvanize policy, research, and community action. Stronger tobacco control, cleaner air, and expanded access to screening and cessation must move in tandem. With sustained effort, the trajectory can be bent, sparing thousands of women—and their families—from preventable loss.
